Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia
Go back to Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 37.39 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.39 | 52 Week High | $71.49 | |||
| Open | $37.39 | 52 Week Low | $33.50 | |||
| Day High | $37.39 | P/E | N/A | |||
| Day Low | $37.39 | EPS | $-1.18 | |||
| Volume | 103 | |||||
